Oppenheimer Maintains Outperform on Relay Therapeutics, Raises Price Target to $18

Oppenheimer analyst Matthew Biegler maintains Relay Therapeutics (NASDAQ:RLAY) with a Outperform and raises the price target from $14 to $18.